Project Grant R01CA308145
Award Date 8/1/26
Completion Date 7/31/31
Dollars Obligated $643K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
St. Louis, MO 63110, USA
Similar Awards
- This five-year $360,281 Project Grant from the National Cancer Institute, part of the Department of Health and Human Services, will fund research under the Cancer Biology Research program (CFDA 93.396). The grantee, Washington University, will conduct studies to define the contribution of altered epigenetic patterns and genome organization to the pathogenesis of acute myeloid leukemia (AML). Researchers will perform comprehensive epigenetic analysis of DNA methylation and three-dimensional...
- The National Cancer Institute, part of the Department of Health and Human Services National Institutes of Health, awarded the University of Missouri System $486,426 on April 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to explore niche-leukemic stem cell interactions and evaluate niche-directed leukemia treatments. The research aims to unravel how minimal residual leukemic stem cells survive within the bone marrow microenvironment, called the niche, which drives therapeutic...
- The National Cancer Institute awarded the University of Chicago $547,740 on July 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to define the molecular mechanisms by which the MLL1 histone modification complex and the long noncoding RNA HOTTIP interact in acute myeloid leukemia pathogenesis. The research examines whether non-specific RNA binding to the WDR5 subunit of the MLL1 complex inhibits the complex's histone methyltransferase activity and whether the RBBP5...
- The National Cancer Institute awarded Northwestern University $593,307 on September 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate molecular mechanisms underlying nucleophosmin 1 (NPM1)-driven acute myeloid leukemia leukemogenesis. The funded research examines how NPM1 cytoplasmic mutations (NPM1c), which occur in approximately 30 percent of adult de novo AML cases, cooperate with clonal hematopoiesis mutations in DNMT3A, TET2, or IDH1/2 to promote leukemic...
- The National Cancer Institute awarded Cincinnati Children's Hospital Medical Center $533,245 on June 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop strategies to eradicate leukemia-initiating cells through investigation of protein glutathionylation regulation. The award supports research examining how post-translational modification of proteins through glutathionylation regulates oxidative phosphorylation in acute myeloid leukemia cells and leukemia-initiating cells,...
- The National Cancer Institute, a division of the Department of Health and Human Services, awarded the University of Illinois $422,649 as a Project Grant (R21CA303745) on June 1, 2026, under the Cancer Biology Research program (CFDA 93.396). The award funds research into racial disparities in acute myeloid leukemia (AML) treatment outcomes. The study examines whether NPM1 mutant status determines FOXM1 cytoplasmic localization and inactivation in primary bone marrow samples from Black AML...
- The National Cancer Institute awarded the University of Wisconsin - Madison $699,587 on August 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to characterize the molecular mechanisms by which MLL-partial tandem duplication (MLLPTD) drives acute myeloid leukemia and myelodysplastic syndromes. The project leverages targeted mass spectrometry and newly developed antibodies to define how allelic complexity modifies MLLPTD protein interactions, chromatin binding, and gene regulatory...
- The National Cancer Institute, part of the Department of Health and Human Services National Institutes of Health, awarded Albert Einstein College of Medicine $431,970 under the Cancer Treatment Research program (CFDA 93.395) on April 1, 2026, to investigate combination approaches to acute myeloid leukemia targeting both CD123-directed NK cell engagers and BCL-2 inhibition through venetoclax. The research will employ dynamic BH3 profiling to probe mitochondrial priming mechanisms and test whether...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $415,259 to the Rector & Visitors of the University of Virginia to conduct research on the role of long noncoding RNAs in acute myeloid leukemia (AML). The project aims to 1) determine the role of a specific regulatory RNA in primary and relapsed AML, and 2) define the mechanism underlying its deregulation in AML. This research will provide insights into how noncoding RNAs...
- The National Cancer Institute awarded The Johns Hopkins University $218,089 on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and test engineered natural killer cell therapy targeting acute myeloid leukemia. The funded work develops chimeric cytokine receptor (CCR)-engineered NK cells designed to attack AML-associated surface antigens and overcome AML-mediated NK cell suppression. In Aim 1, the recipient will engineer NK cells to express dual interleukin...